Food allergy Pipeline Summary

DelveInsight’s, “Food allergy - Pipeline Insight, 2026” report provides comprehensive insights about 28+ companies and 31+ pipeline drugs in Food allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Food allergy: Understanding

Food allergy: Overview

Food allergy is a growing public health concern that affects both children and adults worldwide. It occurs when the immune system mistakenly identifies certain food proteins as harmful and triggers an abnormal immune response, which may range from mild symptoms such as itching and hives to severe, life-threatening anaphylaxis. The most common food allergens include milk, eggs, peanuts, tree nuts, wheat, soy, fish, shellfish, and sesame. Food allergies can be classified as immunoglobulin E (IgE)-mediated or non-IgE-mediated reactions, and their prevalence has increased significantly over recent decades, highlighting the need for accurate diagnosis, effective management, and preventive strategies.

Food allergy is caused by an abnormal immune response to normally harmless food proteins in genetically predisposed individuals. It occurs when the immune system mistakenly identifies specific food allergens as harmful and produces allergen-specific immunoglobulin E (IgE) antibodies. Upon subsequent exposure, these allergens trigger the activation of mast cells and basophils, leading to the release of inflammatory mediators such as histamine and the development of allergic symptoms. Common food allergens include peanuts, tree nuts, milk, eggs, wheat, soy, fish, and shellfish.Food allergy occurs when the immune system mistakenly recognizes a food protein as harmful. In IgE-mediated allergy, exposure to the allergen triggers the release of histamine and other inflammatory mediators from mast cells and basophils, leading to allergic symptoms that can range from mild reactions to severe anaphylaxis.

The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction. The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food.

The treatment of food allergy primarily involves strict avoidance of the allergenic food to prevent allergic reactions while maintaining a balance between effective allergy management and the patient's quality of life. In addition to allergen avoidance, pharmacological therapy is used to manage hypersensitivity reactions. Epinephrine is the first-line and only effective treatment for anaphylaxis, whereas H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors may be used as supportive therapies to relieve allergic symptoms and reduce inflammation, depending on the severity of the reaction.

"Food allergy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Food allergy pipeline landscape is provided which includes the disease overview and Food allergy treatment guidelines. The assessment part of the report embraces, in depth Food allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Food allergy R&D. The therapies under development are focused on novel approaches to treat/improve Food allergy.

Food allergy Emerging Drugs Chapters

This segment of the Food allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Food allergy Emerging Drugs

• Viaskin Peanut: DBV Technologies

Viaskin Peanut (DBV712) is the novel product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center, that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. Currently the drug candidate is in Phase III stage of development for the treatment of peanut allergy. The company announced the intention to submit BLA to US FDA for Peanut hypersensitivity (In children) in the third quarter of 2026.

• PVX108: Aravax

PVX108 investigational precision immunotherapy for the treatment of peanut allergy. It consists of seven synthetic peptides derived from major peanut allergens and is designed to induce immune tolerance without triggering IgE-mediated allergic reactions. Its mechanism of action (MOA) involves selectively targeting allergen-specific CD4? T cells to modulate the immune response, reduce Th2-driven inflammation, and promote long-term tolerance to peanut allergens. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Peanut hypersensitivity, a type of Food allergy.

• MOON101: Moonlight Therapeutics

MOON101 is Moonlight Therapeutics' investigational intradermal allergen immunotherapy for the treatment of peanut allergy. It utilizes a proprietary microneedle skin stamp to deliver small amounts of peanut allergen into the upper layers of the skin, where immune cells are concentrated. Its mechanism of action (MOA) is to modulate the immune system by promoting allergen-specific immune tolerance while minimizing systemic allergen exposure, with the goal of desensitizing patients and reducing the risk of allergic reactions following accidental peanut exposure. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Peanut hypersensitivity, a type of Food allergy.

• LCA-0061: Lycia Therapeutics

LCA-0061 is investigational cataLYTAC™ protein degrader being developed for the treatment of food allergy and other IgE-mediated allergic diseases. Unlike conventional anti-IgE therapies that neutralize circulating IgE, LCA-0061 is designed to catalytically degrade IgE by directing it to the lysosome for destruction. Its mechanism of action (MOA) utilizes Lycia's LYTAC technology to rapidly and durably deplete both free and total IgE, thereby preventing IgE-mediated activation of mast cells and basophils and reducing allergic reactions. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Food allergy.

Further product details are provided in the report……..

Food allergy: Therapeutic Assessment

This segment of the report provides insights about the different Food allergy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Food allergy

There are approx. 28+ key companies which are developing the therapies Food allergy. The companies which have their Food allergy drug candidates in the most advanced stage, i.e. Phase III include, DBV Technologies and others.

• Phases

DelveInsight’s report covers around 31+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Food allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Food allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Food allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Food allergy drugs.

Food allergy Report Insights

• Food allergy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Food allergy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Food allergy drugs?
• How many Food allergy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Food allergy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Food allergy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Food allergy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• DBV Technologies
• Aravax
• Moonlight Therapeutics
• Lycia Therapeutics
• Regeneron Pharmaceuticals Inc.
• GSK plc.
• Novartis AG
• Bambusa Therapeutics
• Intrommune Therapeutics
• Mabylon AG

Key Products

• Viaskin Peanut
• PVX108
• MOON101
• LCA-0061
• Dupilumab / linvoseltamab
• Ozureprubart
• Remibrutinib
• BBT 002
• INT301
• DBV 135
• MY006